Any time there is new or emerging technology that might impact mortality curves, the insurance industry takes notice. And the promise of multi-cancer early detection (MCED) technology certainly ticks that box.
Insurers are favouring funded re as it helps firms manage the market and longevity risks associated with writing bulk purchase annuity (BPA) business by reducing capital charges and therefore making PRT deals more competitive.
Unsurprisingly, given its growth and potential for capital optimisation, UK regulators have been carefully watching the increased use of funded re. In June 2023, the Prudential Regulatory Authority (PRA) sent a “Dear CRO’ letter to heads of risk at UK life insurers.
The letter outlined the regulator’s two main concerns from a sectoral review which it had carried out.
“One of the key risks arising in funded re is that firms recapture sub-optimal portfolios with depressed values and with limited ability to be transformed effectively to the firms’ preferred portfolio,” the PRA letter said.
Post a comment
Related Posts
Life Settlement Market Faces Contrasting Views on Term Life Policy Conversions
Two recent litigation cases produced opposite results for the life settlement market.
Emergence of Buy-In Deals Supports Third Biggest Year on Record for US Pension Risk Transfer Market
Highest ever volume of buy-in transactions show market in maturation stage.
Business as Usual in UK Pension Risk Transfer Market Amid Record Low Mortality in England and Wales
Latest CMI model not likely to have material impact on pensions de-risking activity.
Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet
A new report by reinsurer RGA says that the combination of disease-modifying therapies and better…
